News Alkermes closing in on Biogen with MS rival ALKS 8700 may have fewer side effects than Tecfidera.
News Apitope to develop MS drug, Merck KGaA tie-up ends Anglo-Belgian biotech will continue clinical development.
News Biogen takes on Tecfidera adherence issues Company hopes to coach patients with stomach side-effects.
News Novartis drug effective in advanced MS Siponimod slowed disability progression in secondary progressive multiple sclerosis
News Lilly's 'triple G' retatrutide aces crucial obesity trial Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
